Prosecution Insights
Last updated: November 04, 2026
Application No. 18/551,157

TREATMENT OF HIDRADENITIS SUPPURATIVA WITH ORISMILAST

Non-Final OA §103§112
Filed
Sep 18, 2023
Priority
Mar 22, 2021 — GB 2103975.5 +3 more
Examiner
COPPINS, JANET L
Art Unit
1628
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
UNION THERAPEUTICS A/S
OA Round
2 (Non-Final)
73%
Grant Probability
Favorable
2-3
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 73% — above average
73%
Career Allowance Rate
677 granted / 933 resolved
+12.6% vs TC avg
Strong +26% interview lift
Without
With
+26.1%
Interview Lift
resolved cases with interview
Typical timeline
2y 3m
Avg Prosecution
52 currently pending
Career history
1011
Total Applications
across all art units

Statute-Specific Performance

§101
2.6%
-37.4% vs TC avg
§103
35.2%
-4.8% vs TC avg
§102
15.1%
-24.9% vs TC avg
§112
34.9%
-5.1% vs TC avg
Black line = Tech Center average estimate • Based on career data from 933 resolved cases

Office Action

§103 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Application Status Applicant’s preliminary amendment, submitted June 17, 2026, has been reviewed by the examiner and entered of record in the file. Claims 13, 23 and 26 are amended. Claims 12-31, which were incorrectly numbered in the original claim set because claim number 11 was omitted, are renumbered as claims 11-30. Claims 1-30 are pending, under examination, and are the subject of this office action. Information Disclosure Statement 5. The information disclosure statements (IDS) submitted on June 17, 2026, is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement has been considered by the examiner, please refer to the signed copy of Applicant’s PTO-1449 form, attached herewith. Previous Claim Rejections - 35 USC § 112(b) 6. Claims 24 and 29 (renumbered as claims 23 and 28) were previously rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. 7. Claim 24 (renumbered claim 23) was rejected as being indefinite regarding the recitation of "for example" and the following limitation. In view of Applicant’s deletion of the parenthetical phrase, “for example…[language omitted],” the previous indefiniteness rejection is withdrawn. 8. Claim 29 (renumbered claim 28) was rejected as lacking antecedent basis regarding the limitation "wherein the hydrophilic matric former…" in lines 1-2. In view of the amendatory changes to renumber claims 12-31 as 11-30, renumbered claim 28 depends from claim 14, which now recites the hydrophilic matrix former. Therefore the previous indefiniteness rejection is withdrawn. Previous Claim Rejections - 35 USC § 103 9. Claims 1-10, and original claims 12, 17, 19 and 21 (renumbered as claims 11, 16, 18, and 20), were previously rejected under 35 U.S.C. 103 as being unpatentable over Vossen et al., J Am Acad Dermatol (2018) (cited on Applicant’s IDS of 12/12/23), and further in view of Union Therapeutics, (webpage printout of https://www.prnewswire.com/news-releases/union- therapeutics-as-receives-fda-approval-for-ind-of-oral-next-generation-pde4-inhibitor- orismilast-for-investigation-in-plaque-psoriasis-301202575.html (2021)), (cited on Applicant’s IDS of 12/12/23). 10. Claims 13-16 and 20-31 (renumbered as claims 12-15 and 19-30) were previously rejected as being obvious over Vossen in view of Union Therapeutics and further in view of Rasmussen et al. 11. Claims 5 and original claim 18 (renumbered as claim 17) were previously rejected as being obvious over Vossen in view of Union Therapeutics and further in view of Clinical Trials.gov, as evidenced by PubChem and Elevate:Topical Cream. 12. Original claim 20 (renumbered as claim 19) was previously rejected as being obvious over Vossen in view of Union Therapeutics and further in view of Kerdel et al. 13. Original claims 22-25 (renumbered as claims 21-24) were previously rejected as being obvious over Vossen in view of Union Therapeutics and further in view of Garcovich et al. 14. Original claims 26 and 27 (renumbered as claims 25 and 26) werr previously rejected as being obvious over Vossen in view of Union Therapeutics and further in view of Goldburg et al. 15. Original claim 28 (renumbered as claim 27) was previously rejected as being obvious over Vossen in view of Union Therapeutics and further in view of Schafer et al. Response to Arguments 16. Applicant traverses the previous obviousness rejections, and argues that the previously applied “Union Therapeutics” reference is subject to an exception under 35 U.S.C. §102(b), therefore it cannot be applied for what it describes or teaches in a rejection under 35 U.S.C. §103. Applicant argues that Union Therapeutics is subject to an exception under 35 U.S.C. § 102(b)(1)(A) because this reference published within one year from the effective filing date of the subject application, and the subject matter disclosed was taken directly from the inventors. Applicant submits that the declaration submitted under 37 C.F.R. § 1.130(a) by inventors Morten Sommer and Kim Kjoller establishes that the disclosure of Union was taken directly from the Applicant and inventors. 17. In view of Applicant’s persuasive arguments and the submission of the Declaration under 37 CFR 1.130, declaring that the disclosed subject matter in the Union Therapeutics news release applied in the previous 35 USC 103 rejection was obtained by the inventors, all of the previous obviousness rejections are withdrawn. However, please refer to the new ground(s) of rejection below, which do not rely on the Union Therapeutics reference, applied in the prior rejection of record. New Claim Rejections - 35 USC § 103 18. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action. 19. Claims 1-10, and renumbered claims 11, 16, 18, and 20 (originally numbered as claims 12, 17, 19 and 21), are rejected under 35 U.S.C. 103 as being unpatentable over Vossen et al., J Am Acad Dermatol (2018) (cited on Applicant’s IDS of 12/12/23), in view of Nielsen, Simon, U.S. Pat. No. 20160022657 A1. Claim 1 is drawn to a method of treating hidradenitis suppurativa (HS), comprising orally administering (claims 5 and 11) to a human subject (claim 18) in need thereof a therapeutically effective amount of a compound of formula (I): PNG media_image1.png 362 314 media_image1.png Greyscale or a pharmaceutically acceptable salt, solvate or hydrate thereof, wherein the treatment prevents progression in a subject with moderate HS (claims 2 and 20), and wherein the treatment reduces pain (claim 3) and inflammation (claim 4) caused by or associated with HS, and wherein the compound is administered twice daily (claim 9) at a dose of 30 mg twice per day (claim 10) but no more than 120 mg/day (claim 8), for at least 4 weeks (claim 6), but no more than 20 weeks (claim 7), and is formulated for oral administration (claim 16). 20. Vossen et al. discuss that apremilast, an orally administered PDE4 inhibitor previously showed efficacy for the treatment of hidradenitis suppurativa, i.e., “patients with moderate-to-severe HS treated with apremilast, 30 mg twice daily for 3 months, showed a promising response,” (page 81, left column, second full paragraph). In their study, Vossen et al. demonstrate that apremilast achieved a measurable improvement in patients with moderate HS: “a clinically meaningful improvement of moderate HS after treatment with apremilast at a dose of 30 mg twice per day for 16 weeks. Apremilast significantly decreased disease activity as measured by the AN count, and 53.3% of patients receiving apremilast achieved the HiSCR in comparison with none of the patients receiving placebo,” [emphasis added] (page 85, right column, last paragraph- page 86, left column, first paragraph). A dose of 30 mg twice daily for 16 weeks meets the limitations of claims 6-9 and 11. And, by achieving a significant decrease in disease activity, apremilast treatment is necessarily preventing disease progression (required by claim 2). 21. Vossen et al. demonstrate an overall reduction in inflammation (as measured by a reduction in abscess and inflammatory nodule (AN) count from baseline to week 16) in Figure 4, and an overall reduction in pain levels from baseline to week 16 in Figure 5 and in Table II (see pages 84-85), which meets the limitations of claims 3 and 4. 22. Vossen et al. are silent to the administration of orismilast. However, Vossen et al. go on to teach adverse events of the administration of apremilast in Table III, wherein 47% of patients reported headache, 47% of patients reported diarrhea, 36% of patients reported nausea, 36% of patients reported the common cold, 13% of patients reported vomiting, 13% of patients reported a non-specific rash (see Table III at page 86). 23. And, Nielsen teaches a genus of functionally related benzodioxole-spiro-thiopyran derivatives having PDE4 inhibitory activity upon oral administration that are useful for treating dermal diseases (paragraphs [0010]-[0011] and paragraph [0041], compounds of general formula IIb), and specifically disclose the same compound that is instantly recited by Applicant (i.e., orismilast): PNG media_image2.png 347 283 media_image2.png Greyscale (see page 12, left column). Nielsen goes on to demonstrate the PDE4 inhibitory activity of Compound 108 in the PDE4 Assay of Example 14 (page 15, left column-right column). 24. As such, one of skill in the art before the effective filing date of the claimed invention would have been motivated to modify Vossen et al. and substitute the instantly recited PDE4 inhibitor orismilast for apremilast in the treatment of the dermal disorder hidradenitis suppurativa, with a reasonable expectation of success. And, as noted by the court in In re Font, 675 F.2d 297 (CCPA 1982), an express suggestion to substitute one equivalent component (i.e., an equivalent PDE4 inhibitor) for another is not necessary to render such substitution obvious. In the instant case, (1) the prior art element of Vossen et al. performs the function specified in the claim with only insubstantial differences; (2) the claimed component (i.e. orismilast) and its function was known in the art as disclosed by Nielsen; (3) a person of ordinary skill in the art would have recognized the interchangeability of the elements and could have substituted one known element for another; and (4) the results of the substitution would have been predictable, i.e. a reasonable expectation of success in the treatment of HS in a subject in need thereof. Thus, it would have been obvious to one skilled in the art, having awareness that apremilast administration results in adverse events and side effects, to substitute orismilast for apremilast in the treatment of HS in a subject in need thereof, knowing that orsimilast shows improved efficacy while maintaining good tolerability. As such, claims 1-11, 16, 18, and 20 are prima facie obvious. 25. Claims 12-15 and 28-30, (renumbered), are rejected under 35 U.S.C. 103 as being unpatentable over Vossen et al., J Am Acad Dermatol (2018), in view of Nielsen, Simon, U.S. Pat. No. 20160022657 A1, as applied to claims 1-11, 16, 18, and 20, above, and further in view of Rasmussen et al., WO 2020/148271 A1 (cited on Applicant’s IDS of 12/12/23). Claim 1 is addressed in detail, above. Claim 12 is drawn to claim 1, and limits wherein the compound is comprised within a modified-release formulation, wherein the modified-release formulation additionally comprises a hydrophilic matrix former (claim 14), (more specifically 15% w/w to 25% w/w hydroxypropyl methyl cellulose (claims 15, 28, and 29), and wherein the formulation is in the form of a tablet (claim 30). 26. Vossen et al. in view of Nielsen suggest the oral administration of orismilast for the treatment of moderate HS in a subject in need thereof, but do not teach that orismilast is formulated in a modified-release tablet. 27. Yet, Vossen et al. teach that each group of patients were administered tablets, (i.e., wherein the placebo tablets are identical to apremilast): “Eligible patients were randomly assigned to treatment with apremilast at a dose of 30 mg twice daily (n = 15) or placebo tablets with an appearance, packaging, and labeling identical to that of apremilast (n = 5).” (Page 82, left column, first full paragraph). 28. And, Rasmussen et al. teach the PDE4 inhibitor orismilast, i.e., “Compound A” (see page 3, lines 11-20) formulated in modified-release tablet formulations, comprising 30 mg orismilast and hydroxypropyl methyl cellulose in an amount of 17.5% or 15% w/w (in the form of Methocel® E50 LV) and in an amount of 25% w/w (in the form of Methocel® K100 LV), (see Table 1 at page 10). 29. Rasmussen et al. go on to demonstrate the advantages of the modified-release tablet formulations comprising 30 mg orismilast (shown in Table 1) in Example 3: “When comparing the results shown in Figure 4 (presence of gastrointestinal related adverse events in subjects when dosed with Modified Release tablets containing the PDE4 inhibitor of formula (I)) with the results shown in Figure 5 (presence of gastrointestinal related adverse events in subjects when dosed with Immediate Release tablets containing the PDE4 inhibitor of formula (I)), the Modified Release tablet formulation study shows that the total number of gastrointestinal adverse events was clinically significantly lower when compared to the immediate release tablets.” (Page 12, last paragraph- page 13, lines 1-2). 30. As such, one skilled in the art before the effective filing date of the claimed invention would have been motivated to administer orismilast in the form of a modified- release tablet comprising hydroxypropyl methyl cellulose, in order to minimize potential gastrointestinal side effects that are associated with administration of immediate release orismilast tablets. It would have been obvious to one of skill in the art before the effective filing date of the claimed invention to administer said modified-release tablet comprising orismilast to a patient suffering from moderate HS, and one would have had reasonable expectation of success. As such, claims 12, 14, 15 and 28-30 are prima facie obvious. Claim 13 is drawn to claim 12, wherein the modified-release formulation releases a mean amount of from about 11 % to about 65 % of the compound of formula (I) after 45 minutes and more than 80% of the compound of formula (I) after 180 minutes when placed in a dissolution medium of 900 ml 0.5% sodium dodecyl sulfate in 0.1N HCl using Ph. Eur. 2.9.3 Apparatus II and a paddle speed of 75 rpm. 31. Yet, claim 13 is drafted in terms of the intended outcome of the administration of the modified-release formulation of claim 13: “...wherein the modified-release formulation releases a mean amount of from about 11 % to about 65 % of the compound of formula (I) after 45 minutes and more than 80% of the compound of formula (I) after 180 minutes....” However, a claimed composition maybe obvious because it was suggested by, or structurally similar to, a prior art composition even though a particular benefit of the claimed composition asserted by patentee is not expressly disclosed in the prior art. It is the differences in fact in their respective properties which are determinative of nonobviousness. If the prior art composition does in fact possess a particular benefit, even though the benefit is not recognized in the prior art, Applicant's recognition of the benefit is not in itself sufficient to distinguish the claimed composition from the prior art, In re Dillon, 919 F.2d 688, 16 USPQ2d 1897 (Fed. Cir. 1991). In this case, the mean amount of compound released after 45 minutes or 180 minutes is considered a latent property of the composition disclosed by Rasmussen et al. and the alleged unexpected result of the administration, i.e., the release profile, does not confer patentability. 32. Thus, it would have been obvious to one of skill in the art before the effective filing date of the claimed invention to administer a modified-release formulation comprising orismilast to a patient suffering from moderate HS, wherein said modified-release formulation has the release profile described in claim 14, and one would have had reasonable expectation of success. As such, claim 13 is prima facie obvious. 33. In the alternative, claim 5 and claim 17 are rejected under 35 U.S.C. 103 as being unpatentable over Vossen et al., J Am Acad Dermatol (2018), in view of Nielsen, Simon, U.S. Pat. No. 20160022657 A1, 1-10, and claims 11, 16, 18, and 20 above, and further in view of ClinicalTrials.gov (webpage printout of https://www.clinicaltrials.gov/study/NCT02496546, last updated May 3, 2017), as evidenced by PubChem Compound Summary of Orismilast (webpage printout of https://pubchem.ncbi.nlm.nih.gov/compound/Orismilast, 2025), and as evidenced by Elevate: Topical Cream (Webpage printout of https://www.elevatedermrva.com/topical-cream, 2025). Claim 1 is addressed in detail, above. Claim 5 is drawn to claim 1, wherein treatment comprises topical administration. Claim 17 is drawn to claim 1, and limits wherein the compound is formulated for topical administration. 34. Vossen et al. in view of Nielsen suggest the administration of orismilast for the treatment of moderate HS (a chronic inflammatory skin disorder) in a subject in need thereof, but do not teach that orismilast is formulated for topical administration. 35. However, ClinicalTrials demonstrates the efficacy of topically administering LEO 32731, in the form of a topical cream comprising 20 mg/g LEO 32731, when applied daily for a duration of 3 weeks to adult subjects with atopic dermatitis (a chronic inflammatory condition of the skin), (page 1 under “Study Overview”). And, it is clear as evidenced by PubChem that LEO 32731 is also known as orismilast (page 1 under “Synonyms”). 36. ElevateDermRVA.com teaches the advantages of applying topical creams, i.e., that topical administration of formulations comprising active ingredients offers the advantage of targeted treatment, i.e., a high concentration of medication is delivered directed to the affected area of the skin with minimal systemic absorption, thereby reducing side effects. (Page 1, first paragraph). 37. As such, one of skill in the art before the effective filing date of the claimed invention would have been motivated to administer orismilast in the form of a topical cream to treat HS in a subject in need thereof, in order to deliver a higher concentration of orismilast directed to the affected area of the skin with minimal systemic absorption and reduced side effects. It would have been obvious to one skilled in the art before the effective filing date of the claimed invention to topically administer orismilast in the form of a cream to the affected areas of the skin of a subject in need thereof, with a reasonable expectation of success. Therefore claims 5 and 17 are prima facie obvious. 38. Claim 19 is rejected under 35 U.S.C. 103 as being unpatentable over Vossen et al., J Am Acad Dermatol (2018), in view of Nielsen, Simon, U.S. Pat. No. 20160022657 A1, as applied to claims 1-11, 16, 18, and 20 above, and further in view of Kerdel et al., Journal of Drugs in Dermatology (2019) (cited on Applicant’s IDS of 12/12/23). Claim 1 is addressed in detail, above. Claim 19 is drawn to claim 1, wherein the HS is mild HS. 39. Vossen et al. in view of Nielsen suggest the oral administration of orismilast for the treatment of moderate HS in a subject in need thereof, but do not teach wherein the HS is mild. 40. Yet, Kerdel et al. teach the administration of oral apremilast to patients with mild-to-moderate HS, wherein said patients received apremilast 30mg twice daily. Kerdel et al. teach that a reduction in abscesses and nodules is shown at week 16, and suggest “that apremilast may have a role in the early treatment of less severe HS” (see abstract under “Background,” “Methods,” and “Conclusions”). Kerdel et al. teach adverse events that are consistent with those reported by Vossen et al., i.e., diarrhea (20%), nausea (15%), and depression (10%) were the most commonly reported AEs (see abstract under “Results”). 41. Therefore, one of skill in the art before the effective filing date of the claimed invention would have been motivated to modify Vossen et al. and substitute the instantly recited PDE4 inhibitor orismilast for apremilast in the treatment of mild hidradenitis suppurativa, with a reasonable expectation of success. As such, claim 19 is prima facie obvious. 42. Claims 21-24 are rejected under 35 U.S.C. 103 as being unpatentable over Vossen et al., J Am Acad Dermatol (2018), in view of Nielsen, Simon, U.S. Pat. No. 20160022657 A1, as applied to claims 1-11, 16, 18, and 20 above, above, and further in view of Garcovich et al., Medicine (2020) (cited on Applicant’s IDS of 12/12/23), as evidenced by Hameed et al., World J. Diabetes (2015). Claim 1 is addressed in detail, above. Claim 21 is drawn to claim 1, wherein the HS is severe HS. Claim 22 is drawn to claim 1, wherein the subject is suffering from a comorbidity selected from obesity, metabolic syndrome, spondyloarthopathy, or any combination thereof. 43. Vossen et al. in view of Nielsen suggest the oral administration of orismilast for the treatment of moderate HS in a subject in need thereof, but do not teach wherein the HS is severe or wherein the subject is suffering from a comorbidity. 44. Yet, Garcovich et al. report the use of ampremilast in two patients with severe HS associated with PsA and a complex comorbidity profile including type II diabetes (T2D), wherein both patients were successfully treated with apremilast (see Abstract, under “Patient Concerns”). And, it is clear as evidenced by Hameed et al. that “T2D is a metabolic disorder characterized by insulin resistance and pancreatic β-cell dysfunction as a consequence of unsettled hyperglycemia,” [emphasis added] (Page 599, left column, first paragraph under “Diabetes mellitus- not so sweet”). 45. Thus, it would have been obvious to one of skill in the art before the effective filing date of the claimed invention to modify Vossen et al. and substitute the instantly recited PDE4 inhibitor orismilast for apremilast in the treatment of severe hidradenitis suppurativa in a subject in need thereof, wherein the subject is suffering from a comorbidity that is a metabolic syndrome, with a reasonable expectation of success. As such, claims 21 and 22 are prima facie obvious. Claim 23 is drawn to claim 1, wherein the subject has not been previously treated with biological therapy for HS. 46. Garcovich et al. additionally describe Case 1: “Clinical and patient-reported outcome measures included: the hidradenitis suppurativa-physician global assessment (HS-PGA = 4/severe)... The patient had a BMI = 21.72 and was a cigarette smoker (60 pack-years). He also had numerous comorbidities including NHYA class-III congestive heart disease, type-2 diabetes, iron deficiency anemia related to chronic bleeding from fistulas, and chronic renal insufficiency. Previous treatments included systemic antibiotics (tetracyclines, rifampicin, and clindamycin) for HS, and systemic steroids and NSAIDs for PsA. Based on the clinical profile and contraindication to TNF-alpha antagonists (congestive heart disease), treatment with apremilast (30 mg twice daily) was chosen. After 16 weeks of treatment, clinical and ultrasound examinations showed reduced inflammation and HS disease activity,” [emphasis added] (Page 2, left column, under “2.1. Case 1”). While the patient was previously treated with antibiotics, systemic steroids and NSAIDs, the patient was not treated with any biologics. 47. Therefore it would have been obvious to one of skill in the art before the effective filing date of the claimed invention to modify Vossen et al. and substitute the instantly recited PDE4 inhibitor orismilast for apremilast in the treatment of severe hidradenitis suppurativa in a subject in need thereof, wherein the subject is suffering from a comorbidity that is a metabolic syndrome, and has not been previously treated with any biological therapy, with a reasonable expectation of success. As such, claim 23 is prima facie obvious. Claim 24 is drawn to claim 1, wherein the subject is non-responsive or refractory to biological therapy for HS. 48. Garcovich et al. additionally describe Case 2: “A 51-year-old man was examined for a 7-year duration, severe HS (Hurley III) involving the groins and axillae. Physical examination showed multiple sinus- tracts and nodules on the pubic, inguinal, perianal, and axillary regions (HS-PGA = 5/very severe, NRS pain score 8/10, DLQI = 25) (Fig. 2A and B). The patient was also affected by localized plaque psoriasis and peripheral PsA (DAPSA = 48.2), type-2 diabetes, hypertension, nonalcoholic steatohepatitis, and nephrolithiasis. He smoked 30 pack-years and had BMI = 24. Previous therapies with systemic antibiotics (carbapenems, cotrimaxozole, beta-lactams), cyclosporine, corticosteroids, methotrexate, retinoids, and multiple biologic agents (infliximab, etanercept, adalimumab, secukinumab) were ineffective for both PsA and HS. Extensive surgical treatment of inguinal disease was postponed due to symptomatic nephrolithiasis and high inflammatory load (CRP 6.2 mg/dl). Due to lack of efficacy of previous treatments (adalimumab) and multiple comorbidities, treatment with apremilast (30 mg twice daily) was thus initiated. Apremilast determined a clinically relevant reduction of inflammatory lesions count, effective control of skin-related pain (NRS-pain score 0/10), and QoL-improvement (DLQI = 9) after 16 weeks of treatment (Fig. 2C and D).” (Page 2, right column, under “2.2 Case 2”). Therefore the patient was previously treated with and was non-responsive or refractory to biological therapy for HS. 49. Thus it would have been prima facie obvious to one of skill in the art before the effective filing date of the claimed invention to modify Vossen et al. and substitute the instantly recited PDE4 inhibitor orismilast for apremilast in the treatment of severe hidradenitis suppurativa in a subject in need thereof, wherein the subject is suffering from a comorbidity that is a metabolic syndrome, and is refractory to biological therapy for HS, with a reasonable expectation of success. As such, claim 24 is prima facie obvious. 50. Claims 25 and 26 are rejected under 35 U.S.C. 103 as being unpatentable over Vossen et al., J Am Acad Dermatol (2018), in view of Nielsen, Simon, U.S. Pat. No. 20160022657 A1, in view of claims 1-10, and claims 11, 16, 18, and 20 above, above, and further in view of Goldburg et al., Journal of the American Academy of Dermatology (2020). Claim 1 is addressed in detail, above. Claim 25 is drawn to the method of claim 1 wherein the treatment is administered in combination with a further therapy for HS, (more specifically, wherein the further therapy for HS is selected from: from an anti-androgenic agent, a hormone, a retinoid, an anti-inflammatory agent, an analgesic, an immunosuppressive agent, an antibody, surgery, metformin, a nutritional supplement, a biological therapy for HS, a complement C5a inhibitor, a Janus Kinase (JAK) inhibitor, a leukotriene A4 hydrolase inhibitor, an IRAK4 degrader, an IRAK4 inhibitor, a tyrosine kinase 2 (TYK2) inhibitor, or a TYK2/JAK1 inhibitor or any combination thereof (claim 26)). 51. Vossen et al. in view of Nielsen suggest the oral administration of orismilast for the treatment of moderate HS in a subject in need thereof, but do not teach wherein the orismilast is administered in combination with a further therapy for HS. 52. Yet, Goldburg et al. reports on known medical therapies for HS, including the immunosuppressive agents prednisone, cyclosporine, and dimethyl fumarate; hormones including spironolactone, OCP, cyproterone acetate and ethinyloestradiol, finasteride, dutasteride, and GnRH agonists; retinoids including isotretinoin, acitretin, oral alitretinoin, or etretinate; Metformin; Glp-1 agonists; and biologics including antibodies and JAK inhibitors such as etanercept, CJM-112, bimekizumab, Ustekinumab, MEDI8968, bermekimab, adalimumab, IFX, Anakinra, secukinumab, guselkumab, apremilast, and INCB054707 (see Table I at pages 4-11 and Table III at pages 16-18). 53. Thus, it would have been obvious to one of skill in the art before the effective filing date of the claimed invention to modify Vossen et al. and substitute the instantly recited PDE4 inhibitor orismilast for apremilast in the treatment of HS in a subject in need thereof, in combination with a further therapy for HS, with a reasonable expectation of success. 54. And, the rationale to modify or combine the prior art does not have to be expressly stated in the prior art; the rationale may be expressly or impliedly contained in the prior art or it may be reasoned from knowledge generally available to one of ordinary skill in the art, established scientific principles, or legal precedent established by prior case law, please see In re Fine, 837 F.2d 1071, 5 USPQ2d 1596 (Fed. Cir. 1988); In re Jones, 958 F.2d 347, 21 USPQ2d 1941 (Fed. Cir. 1992). See also In re Kotzab, 217 F.3d 1365, 1370, 55 USPQ2d 1313, 1317 (Fed. Cir. 2000) (setting forth test for implicit teachings); In re Eli Lilly & Co., 902 F.2d 943, 14 USPQ2d 1741 (Fed. Cir. 1990) (discussion of reliance on legal precedent); In re Nilssen, 851 F.2d 1401, 1403, 7 USPQ2d 1500, 1502 (Fed. Cir. 1988) (references do not have to explicitly suggest combining teachings). Furthermore, MPEP 2144 teaches that the strongest rationale for combining references is a recognition, expressly or impliedly in the prior art or drawn from a convincing line of reasoning based on established scientific principles or legal precedent, that some advantage or expected beneficial result would have been produced by their combination. 55. In the instant case, two known compounds/ therapies which individually demonstrate activity against HS could be combined in order to achieve an additive effect in a method of treating HS in a subject in need thereof. Please refer to MPEP 2144.06 “I. COMBINING EQUIVALENTS KNOWN FOR THE SAME PURPOSE” wherein Kerkhoven is specifically referenced: “It is prima facie obvious to combine two compositions each of which is taught by the prior art to be useful for the same purpose, in order to form a third composition to be used for the very same purpose.... [T]he idea of combining them flows logically from their having been individually taught in the prior art.” In re Kerkhoven, 626 F.2d 846, 850, 205 USPQ 1069, 1072 (CCPA 1980) (citations omitted) (Claims to a process of preparing a spray-dried detergent by mixing together two conventional spray-dried detergents were held to be prima facie obvious.). See also In re Crockett, 279 F.2d 274, 126 USPQ 186 (CCPA 1960) (Claims directed to a method and material for treating cast iron using a mixture comprising calcium carbide and magnesium oxide were held unpatentable over prior art disclosures that the aforementioned components individually promote the formation of a nodular structure in cast iron.); and Ex parte Quadranti, 25 USPQ2d 1071 (Bd. Pat. App. & Inter. 1992) (mixture of two known herbicides held prima facie obvious). As stated by the Court in KSR International Co., v. Teleflex Inc., 127 US 1727 (2007), “when a patent ‘simply arranges old elements with each performing the same function it had been known to perform’ and yields no more than one would expect from such an arrangement, the combination is obvious” (quoting Sakraida v. AG Pro, Inc., 425 US 273 (1976); see also: Merck v. Biocraft (874 F.2d 804, 807 (Fed. Cir. 1989), indicating that it is a matter of obviousness for one of ordinary skill in the art to select a particular component from among many disclosed by the prior art as long as it is taught that the selection will result in the disclosed effect, even when the possible selections number 1200 or in the thousands; Sundance, Inc. v. DeMonte Fabricated, Ltd., 550 F.3d 1356 (Fed. Cir. 2008): a claimed invention is obvious is it is a combination of known prior art elements that would reasonably have been expected to maintain their respective properties or functions after they had been combined. 56. Thus, one skilled in the art before the effective filing date of the claimed invention would have been motivated to substitute orismilast for apremilast for treating HS in a subject in need thereof, combined with an additional therapy for HS, and would reasonably expect an additive effect in the treatment of HS in a subject in need thereof. As such, claims 25 and 26 are prima facie obvious. 57. Claim 27 is rejected under 35 U.S.C. 103 as being unpatentable over Vossen et al., J Am Acad Dermatol (2018), in view of Nielsen, Simon, U.S. Pat. No. 20160022657 A1, as applied to claims 1-11, 16, 18, and 20 above, and further in view of Schafer et al., Cellular Signaling (2014). Claim 1 is addressed in detail, above. Claim 27 is drawn to claim 1, wherein the treatment provides selective PDE4D or PDE4B inhibition. 58. Vossen et al. in view of Union Therapeutics suggest the oral administration of orismilast for the treatment of moderate HS in a subject in need thereof, but do not teach wherein the orismilast provides selective PDE4D or PDE4B inhibition. 59. Yet, Schafer et al. report on the pan-PDE4 inhibitory activity of apremilast, specifically naming the isoforms PDE4B and PDE4D: “Apremilast (10 μM) displayed an average of approximately 95% (range:91%– 99%) inhibition of the PDE4 enzymes (A1A, B1, B2, C1, and D2) (Fig. 1). Apremilast did not significantly inhibit the other PDEs tested. Concentration dependent inhibition of these PDE4 isoforms was subsequently confirmed with apremilast IC50 values for PDE4A1A, PDE4B1, PDE4B2, PDE4C1, and PDE4D2 of 14, 43, 27, 118, and 33 nM. This inhibition pattern is consistent with the profile of a pan-PDE4 inhibitor,” [emphasis added] (page 2020, left column, first paragraph under “Results: 3.1 PDE Selectivity”). 60. As such, one of skill in the art would reasonably expect that orismilast, having shown an improved therapeutic window compared to earlier oral PDE4 inhibitors and having demonstrated improved efficacy for inhibiting PDE4, to possess inhibitory activity for PDE4 isoforms PDE4B and PDE4D. 61. Thus, one skilled in the art before the effective filing date of the claimed invention would have been motivated to substitute orismilast for apremilast for treating HS in a subject in need thereof, and would reasonably expect orismilast to have a selective inhibitory effect on PDE4B and PDE4D, and would have had a reasonable expectation of success in the treatment of HS in a subject in need thereof. As such, claim 27 is prima facie obvious. Conclusion 62. In conclusion, claims 1-30 are pending in the instant application, and all claims are currently rejected. No claim is presently allowed. 63. Any inquiry concerning this communication or earlier communications from the examiner should be directed to JANET L COPPINS whose telephone number is (571)272-0680. The examiner can normally be reached Monday-Friday 8:30AM-5PM EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Amy L Clark can be reached at 571-272-1310. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /JANET L COPPINS/Examiner, Art Unit 1628 /AMY L CLARK/Supervisory Patent Examiner, Art Unit 1628
Read full office action

Prosecution Timeline

Sep 18, 2023
Application Filed
Dec 18, 2025
Non-Final Rejection mailed — §103, §112
Jun 17, 2026
Response after Non-Final Action
Jun 17, 2026
Response Filed
Sep 09, 2026
Non-Final Rejection mailed — §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12728129
MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS
4y 8m to grant Granted Sep 08, 2026
Patent 12702150
Methods and Compositions for Slowing an Aging Process in a Human or an Animal
4y 11m to grant Granted Aug 11, 2026
Patent 12673955
NEW CRYSTAL FORM OF P-TOLUENESULFONATE SALT OF DIAZABICYCLIC COMPOUND AND PREPARATION METHOD THEREFOR
3y 4m to grant Granted Jul 07, 2026
Patent 12636297
BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF
4y 5m to grant Granted May 26, 2026
Patent 12611405
AGENT THAT INCREASES THE EXPRESSION OF THE BCL2-ASSOCIATED AGONIST OF CELL DEATH FOR THE TREATMENT OF CANCER
6y 7m to grant Granted Apr 28, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

2-3
Expected OA Rounds
73%
Grant Probability
99%
With Interview (+26.1%)
2y 3m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 933 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month